v3.26.3
Shareholders' Equity (Tables)
 3 Months Ended
Sep. 30, 2026
Shareholders' Equity [Abstract]  
Schedule of Share Options Granted

A summary of the share options granted to non-employee consultants under the Plans by Pluri Inc. and Pluri Biotech is as follows:

  

    Three months ended September 30, 2026  
    Number     Weighted
average
exercise price		     Weighted
average
remaining
contractual
terms
(in years)		     Aggregate
intrinsic
value price		  
Share options outstanding at beginning of period     9,380     $ 7.14       3.46     $ 7  
Share options outstanding at end of the period     9,380     $ 7.14       3.21     $ 3  
Share options vested and exercisable at the end of the period     9,380     $ 7.14       3.21     $ 3  

A summary of the share options granted to the CEO and to a former director under the Plans by Pluri Inc. and Pluri Biotech is as follows:

 

    Three months ended September 30, 2026  
    Number     Weighted
average
exercise price		     Weighted
average
remaining
contractual
terms
(in years)		  
Share options outstanding at the beginning of the period     164,665     $ 12.20       1.02  
Share options expired     (10,463 )   $ 8.96       -  
Share options outstanding at the end of the period     154,202     $ 12.42       0.91  
Share options vested and exercisable at the end of the period     154,202     $ 12.42       0.91  
Schedule of Activity Related to RSUs

The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and Pluri Biotech, for the three-month period ended September 30, 2026:

 

    Three months ended
September 30,
2026		  
    Number  
Unvested at the beginning of the period     270,202  
Granted     211,569  
Forfeited     (23,085 )
Vested     (46,834 )
Unvested at the end of the period     411,852  
Expected to vest after the end of the period     399,783  

The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants by Pluri Inc. and Pluri Biotech for the three-month period ended September 30, 2026:

 

    Three months ended
September 30,		  
    2026  
    Number  
Unvested at the beginning of the period     21,750  
Vested     (1,250 )
Unvested at the end of the period     20,500  
Expected to vest after the end of the period     20,500  
Schedule of Expenses Related to RSUs and RS Granted

Compensation expenses related to RSUs and RS granted by Pluri Inc. and Pluri Biotech were recorded as follows:

 

    Three months ended
September 30,		  
    2026     2025  
Research and development expenses   $ (30 )   $ 122  
General and administrative expenses     256       497  
    $ 226     $ 619